Epigenetics and Cancer: Understanding How Genetic Regulation Beyond DNA Sequencing Influences Tumor Growth, Metastasis, Drug Resistance, and Therapy Response in Precision Medicine

Cancer is driven by genetic and epigenetic alterations that regulate tumor progression, metastasis, and therapy resistance. Epigenetic modifications, including DNA methylation, histone alterations, and non-coding RNA regulation, influence gene expression without altering DNA sequences. Aberrant DNA methylation, histone remodeling, and dysregulated non-coding RNAs contribute to tumor heterogeneity, immune evasion, and drug resistance. Epigenetic mechanisms also drive epithelial-mesenchymal transition (EMT), angiogenesis, and stromal remodeling, facilitating metastasis. Epigenetic biomarkers are being explored for cancer diagnosis, prognosis, and treatment selection, while therapies targeting DNA methylation, histone,modifications, and RNA-based mechanisms show promise. However, challenges remain in specificity, resistance, and multi-omics integration. Future directions include CRISPR-based epigenome editing, AI-driven biomarker discovery, and personalized epigenetic therapies, advancing precision oncology and improving patient outcomes.